Maneka Mirchandaney
Stock Analyst at Evercore ISI Group
(0.22)
# 4,379
Out of 5,182 analysts
9
Total ratings
25%
Success rate
-28.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maneka Mirchandaney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Maintains: Outperform | $45 → $32 | $17.00 | +88.24% | 2 | Apr 2, 2026 | |
| INCY Incyte | Maintains: In-Line | $73 → $110 | $97.77 | +12.51% | 2 | Mar 5, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $41 → $48 | $43.49 | +10.37% | 2 | Sep 11, 2023 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $40 → $30 | $11.19 | +168.10% | 2 | Mar 22, 2023 | |
| HOWL Werewolf Therapeutics | Initiates: Outperform | $23 | $0.62 | +3,609.68% | 1 | May 25, 2021 |
Viridian Therapeutics
Apr 2, 2026
Maintains: Outperform
Price Target: $45 → $32
Current: $17.00
Upside: +88.24%
Incyte
Mar 5, 2026
Maintains: In-Line
Price Target: $73 → $110
Current: $97.77
Upside: +12.51%
Crinetics Pharmaceuticals
Sep 11, 2023
Maintains: Outperform
Price Target: $41 → $48
Current: $43.49
Upside: +10.37%
MiNK Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $40 → $30
Current: $11.19
Upside: +168.10%
Werewolf Therapeutics
May 25, 2021
Initiates: Outperform
Price Target: $23
Current: $0.62
Upside: +3,609.68%